| Literature DB >> 22920732 |
Nicholas A P S Buss1, Simon J Henderson, Mary McFarlane, Jacintha M Shenton, Lolke de Haan.
Abstract
Over the last three decades, monoclonal antibodies have made a dramatic transformation from scientific tools to powerful human therapeutics. At present, approximately 30 therapeutic monoclonal antibodies are marketed in the United States and Europe in a variety of indications, with sales in the US alone reaching approximately $18.5 billion in 2010. This review describes how antibody engineering has revolutionized drug discovery and what are considered the key areas for future development in the monoclonal antibody therapy field.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22920732 DOI: 10.1016/j.coph.2012.08.001
Source DB: PubMed Journal: Curr Opin Pharmacol ISSN: 1471-4892 Impact factor: 5.547